Investor Relations | JamJoom Pharma

Our theme “Together Healthier”

Jamjoom Pharma: Leading the Future of Accessible Healthcare in the Middle East and Africa.

At Jamjoom Pharma, our story is one of purpose, progress, and people. What began over 20 years ago as a visionary goal to localize world-class pharmaceutical production in Saudi Arabia has evolved into a healthcare movement that’s changing lives across the Middle East and Africa.

From day one, we believe that high-quality, affordable healthcare should never be a privilege it should be a promise. Today, that promise lives through every product we manufacture, every community we serve, and every innovation we pursue

With four cutting-edge pharmaceutical manufacturing facilities and a dynamic presence in 36 countries, Jamjoom Pharma is at the heart of regional healthcare transformation.

More than a pharmaceutical company, we are a trusted healthcare partner advancing local production, aligning with Saudi Vision 2030, and investing in digital innovation and sustainability. We are driving change, championing access, and shaping a healthier tomorrow.

Investment Case

Jamjoom Pharma offers a compelling investment opportunity, underpinned by strong financial performance, strategic growth initiatives, and a proven track record of delivering value to stakeholders. Our position as a leading pharmaceutical company in the Middle East and Africa region makes us uniquely suited to capitalize on emerging opportunities in the global healthcare sector.

Strong Financial Performance

Consistent revenue growth with SAR 1.3 billion in 2024, reflecting a robust 19.8% YoY increase.

High profitability with a net profit margin of 27% and an EBITDA margin of 33.2%.

Strong free cash flow conversion of 87%, demonstrating financial5 stability and operational efficiency.

Market  Leadership

Dominant market share in key therapeutic areas such as ophthalmology and dermatology.

Expanding footprint across 36 countries with significant growth in high-potential markets like Egypt, Algeria, and the Gulf.

Established partnerships with healthcare providers and government agencies to drive regional market leadership.

Innovative Product Portfolio

Launch of 9 new brands in 2024, including advancements in consumer health and anti-diabetics.

Robust pipeline targeting high- growth areas such as Cardiovascular, gastrointestinal, and biologics.

Commitment to addressing unmet medical needs through continuous R&D investments.

State-of-the-Art Infrastructure

Fully operational Jeddah Sterile Facility, enabling production of high- demand ophthalmology products.

Expansion of manufacturing capacity in Egypt to support regional self- sufficiency and market demand.

Al-driven technologies enhancing operational efficiency and scalability.

Alignment with Vision 2030

Key contributor to Saudi Vision 2030 goals by promoting local pharmaceutical manufacturing and job creation.

Commitment to sustainable practices, including energy-efficient production and reduced environmental impact.

Experienced Leader-ship and Governance

Led by an experienced management team with a proven track record of delivering results.

Strong corporate governance framework, ensuring transparency and accountability.

Growth Potential in Emerging Markets

High-growth opportunities in underserved regions, supported by tailored market-entry strategies.

Strategic focus on expanding presence in Francophone Africa and other emerging markets.

Jamjoom Pharma in Numbers

Proof in Performance: Metrics That Tell Our Story

At Jamjoom Pharma, every number tells a story of impact, trust, and forward momentum. Behind our financial achievements and operational milestones is a deeper mission—to transform healthcare delivery across the Middle East and Africa with precision, purpose, and accessibility.

*All figures are 9M 2025

Announcements

Events

Our CEO’s Message

Our CEO’s Message

A Year of Progress, Purpose & People

2024 marked a pivotal chapter in Jamjoom Pharma’s journey one defined not just by outcomes, but by the values and vision that have consistently shaped who we are.

At our core, we are a purpose-driven organization. Every milestone from launching innovative brands to operationalizing advanced manufacturing facilities is a reflection of our commitment to making healthcare more accessible, more responsive, and more aligned with the needs of our communities across the Middle East and Africa.

We continued to invest in infrastructure, R&D, digital transformation, & our people ensuring our evolution remains rooted in excellence and long-term impact. The full commissio-ning of the Jeddah Sterile Facility and our expansion of regional production capacity represent strategic steps toward pharmaceutical self-sufficiency and sustainability.

Beyond operations, our culture remains our foundation. Through the Jamjoom Pharma Academy, inclusive employment, and a steadfast focus on Saudization, we are nurturing talent and leadership for the future. We take pride in being one of the first in our sector to promote female employment in our manufacturing lines—an achievement that reflects both our values and our vision.

Looking ahead, we will continue to align with the ambitions of Saudi Vision 2030, not only by contributing to healthcare localization but by setting benchmarks in innovation, governance, and operational agility.

Together with our partners, team, and stakeholders, we reaffirm our commitment to shaping a healthier, more sustainable future. Thank you for being part of our mission to make the region —Together Healthier.

Tarek Hosni

CEO of Jamjoom Pharma

Latest Earnings Reports

Awards & Recognitions

Industry Leadership

Ranked among the top pharmaceutical companies in the Middle East by industry analysts.

Corporation Excellence

Received accolades for operational efficiency and market leadership, including inclusion in the FTSE Mid Cap and Global Equity Index.

CEO Recognition

The CEO was honored as one of the Top CEQs in the Middle East for 2024 by Forbes Middle East.

Export Achievement

Recognized by the Saudi Exports Development Authority for outstanding contributions to regional healthcare exports.

Sustainability Initiative

Strengthened our commitment to local production through a landmark agreement with the KSA ‘Local Content Authority’ positioning JP as the preferred supplier of Sitagliptin from 2026 onward to meet the growing demand of the governmental and institutional healthcare sector.

Quick Links